FIGURE 2.

Navitoclax decreased senescent cell burden in BMSC and osteogenic cultures. Primary BMSC were harvested from 24 month old male and female mice and treated with navitoclax (5 μM) or vehicle (DMSO) for 5 days in BMSC growth medium (A,B), osteogenic medium (C,D), or osteogenic medium with 100 nM dexamethasone (E,F). Senescent cells were identified by blue staining and quantified relative to total cell number. Representative images for each condition are shown in (A,C,E). Scale bar: 100 μm. P-values shown represent statistical comparisons between groups, p-value for “drug” in 2-factor ANOVAs represents the comparison between navitoclax (gray) and vehicle (white)-treated cultures.